Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI
09 Julio 2019 - 7:30AM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an
update that Sandoz Inc. (Sandoz), a Novartis division, today
announced the U.S. retail launch of SYMJEPI™ (epinephrine) 0.3 mg
and 0.15 mg Injections, making both the adult and pediatric doses
immediately available in local pharmacies across the U.S.
Sandoz launched SYMJEPI 0.3 mg Injection in the institutional
channel earlier this year, and large wholesaler customers of Sandoz
are now fully stocked to supply hospitals and clinics with both
SYMJEPI 0.3 mg and 0.15 mg Injections inventory in the U.S.
Sandoz also announced that in preparation for the U.S. retail
launch they have rolled out the following:
- A social media program to increase awareness among physicians
and patients;
- The new SYMJEPI website (https://www.symjepi.com/) to provide
an instructional video and additional information on the
product;
- A demonstrator device that simulates the use of SYMJEPI;
- The SYMJEPI Savings Program, in which eligible patients pay as
little as $0;
- An initiative to modify existing state legislation to increase
the availability of epinephrine in schools; and,
- A campaign to educate hospital providers and physicians on how
to write scripts for epinephrine injection.
Dr. Dennis J. Carlo, President and CEO of Adamis stated, “Along
with Sandoz, Adamis is thrilled to bring broad access to this
critical medicine for patients. We expect that SYMJEPI will
play a role in ending the chronic shortages of epinephrine
injection products in the U.S.,” said Dr. Dennis J. Carlo,
President and CEO of Adamis.
About Adamis
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
respiratory disease and allergy. The company’s SYMJEPI
(epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection
0.15mg products are FDA approved for use in the emergency treatment
of acute allergic reactions, including anaphylaxis. Adamis is
developing additional products, including a naloxone injection
product candidate for the treatment of opioid overdose, and a
metered dose inhaler and dry powder inhaler product candidates for
the treatment of asthma and COPD. The company’s subsidiary,
U.S. Compounding, Inc., compounds sterile prescription drugs, and
certain nonsterile drugs for human and veterinary use, to patients,
physician clinics, hospitals, surgery centers and other clients
throughout most of the United States.
Adamis Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements relate to future events or future
results of operations, including, but not limited to the following
statements: the company’s beliefs concerning the timing of
commercial launch of its Symjepi (epinephrine) Injection 0.3mg
product; the company’s beliefs concerning the commercial success of
its Symjepi product if and when launched; the company’s ability to
provide an appropriate supply of product for launch and thereafter;
the company’s beliefs concerning the resources and capabilities
that are required to provide access to its Symjepi product; the
company’s beliefs concerning timing and outcome of finalizing the
commercialization arrangements and strategy for its Symjepi
products; the company’s ability to commercialize its product and
product candidates; the company’s beliefs concerning the ability of
its products and product candidates to compete successfully in the
market; the company’s beliefs concerning the safety and
effectiveness of its products and product candidates; anticipated
dates for commercial introduction of products; guidance regarding
future periods; and other statements concerning our future
operations and activities. Such forward-looking statements
include those that express plans, anticipation, intent,
contingencies, goals, targets or future development and/or
otherwise are not statements of historical fact. These
statements are only predictions, are not guarantees, involve known
and unknown risks, uncertainties and other factors, and concern
matters that could subsequently differ materially from those
described in this press release, which may cause Adamis' actual
results to be materially different from those contemplated by these
forward-looking statements. In addition, forward-looking
statements concerning our anticipated future activities assume that
we are able to obtain sufficient funding to support such activities
and continue our operations and planned activities. As
discussed in our filings with the Securities and Exchange
Commission, we may require additional funding, and there are no
assurances that such funding will be available if required.
We cannot assess the impact of each factor on our business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward-looking statements. You should not place undue
reliance on any forward-looking statements. Further, any
forward-looking statement speaks only as of the date on which it is
made, and except as may be required by applicable law, we undertake
no obligation to update or release publicly the results of any
revisions to these forward-looking statements or to reflect events
or circumstances arising after the date of this press
release. Certain of these risks, and additional risks,
uncertainties, and other factors are described in greater detail in
Adamis’ filings from time to time with the SEC, including its
annual report on Form 10-K for the year ended December 31, 2017,
and our subsequent filings with the SEC, which Adamis strongly
urges you to read and consider, all of which are available free of
charge on the SEC's web site at http://www.sec.gov.
Contacts: Mark Flather Senior Director,
Investor Relations& Corporate Communications Adamis
Pharmaceuticals Corporation (858)
412-7951mflather@adamispharma.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024